Photo Denis Barrier

Denis Barrier

Co-founder and CEO

Cathay Innovation

#
Climate Tech
Mobility & Smart Cities
Healthcare & Wellness

About Me

Denis is Co-founder and Managing Partner of Cathay Innovation, Cathay Capital's Venture Capital practice. Prior to Cathay, he was at Iris Capital where he managed the international activities of the Orange/Publicis fund. He has also been the Head of Corporate Venture at Orange Telecom, Managing Director at Innovacom, and has worked as an Officer at the French Treasury Department, in charge of all the Sovereign holdings in Aerospace, Defense, and Media companies. Denis has pioneered a unique way to invest in technology, leveraging the traditional playbook of venture capital investing, but also integrating the larger social evolutions at play, analyzing the competitive landscape at a fully global level, and integrating in the insights of numerous Fortune 500 companies committed in his ecosystem in the due diligence process. He believes that this fosters deeper relationships with entrepreneurs from the start and helps them lead faster and further on the global stage. Denis has a deep technical background and started as a Researcher in the laboratories of Orange Telecom, working on semiconductor quantum dots. He holds a Ph.D. in solid state Physics, is a graduate of Ecole Normale Supérieure, and is an engineer of Ecole Nationale Supérieure des Télécommunications.

Hear My Insights

AI-Powered Drug Innovation: From Discovery to Development

AI-Powered Drug Innovation: From Discovery to Development The traditional journey of drug discovery and development is long, expensive, and fraught with uncertainty. Today, artificial intelligence is transforming this paradigm, offering the potential to significantly compress timelines across the entire spectrum, from initial target identification through preclinical studies and clinical trials. By enabling sophisticated modeling of biological systems and patient responses with exceptional precision, AI is not only accelerating the identification of promising drug candidates but also optimizing their development pathways. This session will explore what breakthroughs are already reshaping the field—and which are just around the corner. What are the strategic and regulatory hurdles to integrating these tools into an industry built on rigorous validation? And how can we harness the full promise of AI while safeguarding the trust, safety, and ethics that underpin medical innovation?